701-1133

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2012-10-28

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-27 (study day 61.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-27 (study day 61.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-27 (study day 61.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-27 (study day 61.0); relationship: PROBABLE

Data queries

No data queries.